Marshall Wace’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-7,505
| Closed | -$1.5M | – | 3480 |
|
|
2026
Q1 | $1.5M | Buy |
+7,505
| New | +$1.48M | ﹤0.01% | 1939 |
|
|
2024
Q2 | – | Sell |
-6,636
| Closed | -$485K | – | 2763 |
|
|
2024
Q1 | $485K | Buy |
+6,636
| New | +$489K | ﹤0.01% | 1933 |
|
|
2023
Q4 | – | Sell |
-6,333
| Closed | -$379K | – | 2423 |
|
|
2023
Q3 | $379K | Buy |
+6,333
| New | +$417K | ﹤0.01% | 1802 |
|
|
2023
Q2 | – | Sell |
-27,583
| Closed | -$2.03M | – | 2735 |
|
|
2023
Q1 | $2.03M | Sell |
27,583
-65,280
| -70% | -$4.64M | ﹤0.01% | 1454 |
|
|
2022
Q4 | $6.2M | Buy |
92,863
+28,931
| +45% | +$1.88M | 0.01% | 1053 |
|
|
2022
Q3 | $3.43M | Hold |
63,932
| – | – | 0.01% | 1656 |
|
|
2022
Q2 | $3.56M | Buy |
+63,932
| New | +$3.63M | 0.01% | 1602 |
|
|
2021
Q4 | – | Sell |
-14,068
| Closed | -$1.22M | – | 4102 |
|
|
2021
Q3 | $1.22M | Buy |
+14,068
| New | +$1.09M | 0.01% | 1896 |
|
|
2021
Q1 | – | Sell |
-10,283
| Closed | -$638K | – | 2693 |
|
|
2020
Q4 | $638K | Buy |
+10,283
| New | +$586K | ﹤0.01% | 1377 |
|
|
2020
Q2 | – | Sell |
-8,140
| Closed | -$369K | – | 1785 |
|
|
2020
Q1 | $369K | Buy |
+8,140
| New | +$461K | ﹤0.01% | 1044 |
|
|
2019
Q3 | – | Sell |
-48,419
| Closed | -$3.45M | – | 1807 |
|
|
2019
Q2 | $3.45M | Sell |
48,419
-41,607
| -46% | -$3.06M | 0.03% | 605 |
|
|
2019
Q1 | $7.06M | Sell |
90,026
-157,694
| -64% | -$11.9M | 0.07% | 355 |
|
|
2018
Q4 | $21M | Buy |
247,720
+245,965
| +14,015% | +$26.2M | 0.21% | 107 |
|
|
2018
Q3 | $301K | Sell |
1,755
-7,321
| -81% | -$1.1M | ﹤0.01% | 1011 |
|
|
2018
Q2 | $1.17M | Buy |
+9,076
| New | +$1.01M | 0.02% | 491 |
|
|
2015
Q1 | – | Sell |
-152,490
| Closed | -$5.06M | – | 874 |
|
|
2014
Q4 | $5.06M | Sell |
152,490
-158,782
| -51% | -$5.17M | 0.07% | 310 |
|
|
2014
Q3 | $9.12M | Buy |
311,272
+305,841
| +5,631% | +$10.2M | 0.13% | 195 |
|
|
2014
Q2 | $211K | Sell |
5,431
-70,344
| -93% | -$2.85M | ﹤0.01% | 842 |
|
|
2014
Q1 | $3.18M | Buy |
+75,775
| New | +$3.16M | 0.06% | 286 |
|
Other funds holding LGND
Marshall Wace's LGND Position: Q2 2026 in Review
Marshall Wace sold out of Ligand Pharmaceuticals (LGND) in Q2 2026, closing a stake of 7,505 shares — an estimated $1.5M sold.
Marshall Wace first reported a position in LGND in Q1 2014 and held it in 19 quarters. The position peaked at $21M in Q4 2018. 420 funds tracked by Wall St. Rank hold LGND as of Q2 2026.
- Marshall Wace reported no remaining Ligand Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Marshall Wace sold 7,505 Ligand Pharmaceuticals shares in Q2 2026, an estimated $1.5M.
- Marshall Wace first reported a position in Ligand Pharmaceuticals in Q1 2014 and held it in 19 quarters.
- Marshall Wace's Ligand Pharmaceuticals position peaked at $21M in Q4 2018.
- 420 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.
Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.